Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study.

Kakegawa T, Sugimoto K, Saito K, Yunaiyama D, Araki Y, Wada T, Takahashi H, Yoshimasu Y, Takeuchi H, Itoi T

Medicine1 Jun 2024Cited by 26 (Europe PMC)

PMID38847728PMCIDPMC11155541DOI10.1097/md.0000000000038444PepBankPUB-38847728

Summary

To investigate changes in skeletal muscle mass and fat fraction in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) undergoing treatment with Semaglutide for 6months. This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM. Body weight, metabolic parameters, liver enzymes, fibrosis markers, skeletal muscle index (cm2/m2), and fat fraction (%) at the L3 level using the two-point Dixon method on magnetic resonance imaging (MRI), as well as liver steatosis and liver stiffness assessed using MRI-based proton density fat fraction (MRI-PDFF) and MR elastography, respectively, were prospectively examined before and 6 months after semaglutide administration. The mean age of the patients was 53 years and 47.6% were females. The median liver steatosis-fraction (%) and skeletal muscle steatosis-fraction values (%) significantly decreased (22.0 vs 12.0; P = .0014) and (12.8 vs 9.9; P = .0416) at baseline and 6 months, respectively, while maintaining muscle mass during treatment. Semaglutide also dramatically reduced hemoglobin A1c (%) (6.8 vs 5.8, P = .0003), AST (IU/L) (54 vs 26, P < .0001), ALT (IU/L) (80 vs 34, P = .0004), and γ-GTP (IU/L) levels (64 vs 34, P = .0007). Although not statistically significant, Body weight (kg) (79.9 vs 77.4), body mass index (BMI) (kg/m2) (28.9 vs 27.6), and liver stiffness (kPa) (28.9 vs 27.6) showed a decreasing trend. Fibrosis markers such as M2BPGi, type IV collagen, and skeletal muscle area did not differ. Semaglutide demonstrated favorable effects on liver and skeletal muscle steatosis, promoting improved liver function and diabetic status.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanObservational studyEfficacy outcome
In adults with MASLD and type 2 diabetes, median liver steatosis fraction fell significantly after 6 months of semaglutide.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, liver fat fell after 6 months of semaglutide, with no control group.
Peptide
Semaglutide
Outcome
DecreaseLiver steatosis fraction
Study
n = 21
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Median liver steatosis fraction
22 to 12%
baseline to 6 months
Source sentences
Summary
The median liver steatosis-fraction (%) and skeletal muscle steatosis-fraction values (%) significantly decreased (22.0 vs 12.0; P = .0014)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM.
Show in the study text Report a problemFND-3884772801
02HumanObservational studyEfficacy outcome
In adults with MASLD and type 2 diabetes, median skeletal muscle steatosis fraction fell significantly after 6 months of semaglutide.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, fat in the muscle fell after 6 months of semaglutide, with no control group.
Peptide
Semaglutide
Outcome
DecreaseSkeletal muscle steatosis fraction
Study
n = 21
Comparator
Baseline
Outcome group
Liver fat and liver function · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Median skeletal muscle steatosis fraction
12.8 to 9.9%
baseline to 6 months
Source sentences
Summary
The median liver steatosis-fraction (%) and skeletal muscle steatosis-fraction values (%) significantly decreased (22.0 vs 12.0; P = .0014) and (12.8 vs 9.9; P = .0416) at baseline and 6 months, respectively, while maintaining muscle mass during treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM.
Show in the study text Report a problemFND-3884772802
03HumanObservational studyEfficacy outcome
In adults with MASLD and type 2 diabetes, skeletal muscle mass was maintained during 6 months of semaglutide.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, muscle mass was maintained during 6 months of semaglutide.
Peptide
Semaglutide
Outcome
No significant changeSkeletal muscle mass
Study
n = 21
Comparator
Baseline
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
while maintaining muscle mass during treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM.
Show in the study text Report a problemFND-3884772803
04HumanObservational studyEfficacy outcome
In adults with MASLD and type 2 diabetes, hemoglobin A1c fell after 6 months of semaglutide.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, blood sugar control (HbA1c) improved after 6 months of semaglutide, with no control group.
Peptide
Semaglutide
Outcome
DecreaseHemoglobin A1c
Study
n = 21
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Hemoglobin A1c
6.8 to 5.8%
baseline to 6 months
Source sentences
Summary
Semaglutide also dramatically reduced hemoglobin A1c (%) (6.8 vs 5.8, P = .0003)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM.
Show in the study text Report a problemFND-3884772804
05HumanObservational studyEfficacy outcome
In adults with MASLD and type 2 diabetes, AST fell after 6 months of semaglutide.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, the liver enzyme AST fell after 6 months of semaglutide, with no control group.
Peptide
Semaglutide
Outcome
DecreaseAST
Study
n = 21
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
AST
54 to 26 IU/L
baseline to 6 months
Source sentences
Summary
AST (IU/L) (54 vs 26, P < .0001)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM.
Show in the study text Report a problemFND-3884772805
06HumanObservational studyEfficacy outcome
In adults with MASLD and type 2 diabetes, ALT fell after 6 months of semaglutide.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, the liver enzyme ALT fell after 6 months of semaglutide, with no control group.
Peptide
Semaglutide
Outcome
DecreaseALT
Study
n = 21
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
ALT
80 to 34 IU/L
baseline to 6 months
Source sentences
Summary
ALT (IU/L) (80 vs 34, P = .0004)
1 context sentence(design, population, supporting numbers)
Summary · context
This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM.
Show in the study text Report a problemFND-3884772806
07HumanObservational studyEfficacy outcome
In adults with MASLD and type 2 diabetes, gamma-GTP fell after 6 months of semaglutide.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, the liver enzyme gamma-GTP fell after 6 months of semaglutide, with no control group.
Peptide
Semaglutide
Outcome
DecreaseGamma-GTP
Study
n = 21
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
gamma-GTP
64 to 34 IU/L
baseline to 6 months
Source sentences
Summary
γ-GTP (IU/L) levels (64 vs 34, P = .0007).
1 context sentence(design, population, supporting numbers)
Summary · context
This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM.
Show in the study text Report a problemFND-3884772807
08HumanObservational studyEfficacy outcome
In adults with MASLD and type 2 diabetes, body weight showed a decreasing trend that was not statistically significant after 6 months of semaglutide.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, body weight trended down after 6 months of semaglutide, but not significantly.
Peptide
Semaglutide
Outcome
No significant changeBody weight
Study
n = 21
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Body weight
79.9 to 77.4 kg
baseline to 6 months
Source sentences
Summary
Although not statistically significant, Body weight (kg) (79.9 vs 77.4), body mass index (BMI) (kg/m2) (28.9 vs 27.6), and liver stiffness (kPa) (28.9 vs 27.6) showed a decreasing trend.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM.
Show in the study text Report a problemFND-3884772808
09HumanObservational studyEfficacy outcome
In adults with MASLD and type 2 diabetes, body mass index showed a decreasing trend that was not statistically significant after 6 months of semaglutide.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, body mass index trended down after 6 months of semaglutide, but not significantly.
Peptide
Semaglutide
Outcome
No significant changeBody mass index
Study
n = 21
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
BMI
28.9 to 27.6 kg/m2
baseline to 6 months
Source sentences
Summary
Although not statistically significant, Body weight (kg) (79.9 vs 77.4), body mass index (BMI) (kg/m2) (28.9 vs 27.6), and liver stiffness (kPa) (28.9 vs 27.6) showed a decreasing trend.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM.
Show in the study text Report a problemFND-3884772809
10HumanObservational studyEfficacy outcome
In adults with MASLD and type 2 diabetes, liver stiffness showed a decreasing trend that was not statistically significant after 6 months of semaglutide.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, liver stiffness trended down after 6 months of semaglutide, but not significantly.
Peptide
Semaglutide
Outcome
No significant changeLiver stiffness
Study
n = 21
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Although not statistically significant, Body weight (kg) (79.9 vs 77.4), body mass index (BMI) (kg/m2) (28.9 vs 27.6), and liver stiffness (kPa) (28.9 vs 27.6) showed a decreasing trend.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM.
Show in the study text Report a problemFND-3884772810
11HumanObservational studyEfficacy outcome
In adults with MASLD and type 2 diabetes, the fibrosis markers M2BPGi and type IV collagen did not differ after 6 months of semaglutide.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, liver scarring markers did not change after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
No significant changeFibrosis markers (M2BPGi, type IV collagen)
Study
n = 21
Comparator
Baseline
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Fibrosis markers such as M2BPGi, type IV collagen, and skeletal muscle area did not differ.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM.
Show in the study text Report a problemFND-3884772811
12HumanObservational studyEfficacy outcome
In adults with MASLD and type 2 diabetes, skeletal muscle area did not differ after 6 months of semaglutide.
In plain wordsIn adults with fatty liver disease and type 2 diabetes, muscle area did not change after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
No significant changeSkeletal muscle area
Study
n = 21
Comparator
Baseline
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Fibrosis markers such as M2BPGi, type IV collagen, and skeletal muscle area did not differ.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-arm pilot study included 21 patients with MASLD who received semaglutide for T2DM.
Show in the study text Report a problemFND-3884772812

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.